Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Crocs, Inc. ( CROX - Snapshot Report ) recently amended its existing revolving credit agreement. The amendment increased the size of the revolving credit line from $70 million to $100 million and has extended the maturity period from four years to five years. Moreover, the company expects to lower the borrowing costs based on the 50 basis points reduction in interest rate as compared with the previous credit agreement due 2016.
The revolving credit facility is arranged by PNC Bank, N.A., a member of The PNC Financial Services Group, Inc. ( PNC - Analyst Report ) , JPMorgan Chase Bank- a part of JPMorgan Chase & Co. ( JPM - Analyst Report ) and Wells Fargo Bank- an associate of Wells Fargo & Company ( WFC - Analyst Report ) .
Crocs’ Chief Financial Officer, Jeff Lasher, was pleased with the favorable fee structure, which resulted from the amendment. He opined that the new agreement will create immediate savings and help in easy execution of business with increased credit size and extended term. Additionally, the shoe manufacturer will now be able to invest more into its business for growth and enhance shareholder value as well.
In October 2011, Crocs released its third-quarter 2012 financial results. The company earned 49 cents per share in the third quarter of 2012, ahead of the Zacks Consensus Estimate of 43 cents per share as well as last year’s 33 cents per share.
Quarterly revenues jumped 7.5% year over year to $295.6 million, driven by strong sales growth in Asia (up 11.3%) and America (up 7.4%), partially offset by soft business in Europe (down 2.9%) owing to the challenging macroeconomic conditions. Sales grew 1.5% at wholesale and 17.7% at Retail. Gross profit enhanced 9.2% to $160.7 million.
For the fourth quarter of 2012, the company expects break-even earnings per share on revenue of $220 million.
Based in Niwot, Colorado, Crocs is a rapidly growing designer, manufacturer and marketer of footwear for men, women and children under the CROCS brand. We currently maintain our long-term ‘Underperform’ recommendation on the stock. Moreover, Crocs has a Zacks #4 Rank, which translates into a short-term (1-3 months) ‘Sell’ rating.
Read the full reports :
Analyst Report on JPM
Analyst Report on PNC
Analyst Report on WFC
Snapshot Report on CROX